Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of
Non-small Cell Lung Cancer with MET Alterations.
10.3779/j.issn.1009-3419.2023.102.33
- Author:
Shuzhan LI
1
;
Xinwei ZHANG
1
Author Information
1. Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China.
- Publication Type:Journal Article
- Keywords:
Drug resistance;
Lung neoplasms;
Mesenchymal to epithelial transition factor;
Targeted therapy;
Treatment strategy
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/pathology*;
Lung Neoplasms/pathology*;
ErbB Receptors/genetics*;
Drug Resistance, Neoplasm/genetics*;
Protein Kinase Inhibitors/therapeutic use*;
Epithelial-Mesenchymal Transition;
Mutation
- From:
Chinese Journal of Lung Cancer
2023;26(9):684-691
- CountryChina
- Language:Chinese
-
Abstract:
Mesenchymal to epithelial transition factor (MET) gene alterations involve in the proliferation, invasion, and metastasis of non-small cell lung cancer. MET-tyrosine kinase inhibitors (TKIs) have been approved to treat non-small cell lung cancer with MET alterations, and resistance to these TKIs is inevitable. Molecular mechanisms of resistance to MET-TKIs are completely unclear. The review focused on potential mechanisms of MET-TKIs resistance and therapeutics strategies to delay and prevent resistance.
.
